Inhibitec

Inhibitec is a private, preclinical-stage biotech spin-off from the University of Cantabria and the Spanish National Research Council (CSIC). The company is advancing a first-in-class, humanized monoclonal antibody (hB101.37) that inhibits BAMBI, a key regulator of CD4 T-cell differentiation. This approach aims to simultaneously reduce pro-inflammatory Th17 cells and enhance regulatory T cells (Tregs), offering a novel therapeutic strategy for psoriatic arthritis and related conditions. The company is backed by national grants, international recognition from the National Psoriasis Foundation, and holds an exclusive license to the foundational patent.

Platform centered on inhibiting BAMBI (BMP and Activin Membrane-Bound Inhibitor) using monoclonal antibodies. This approach uniquely modulates TGF-β signaling in CD4+ T cells to simultaneously reduce pro-inflammatory Th17 cells and enhance regulatory T cells (Tregs).

Inhibitec competes in the crowded psoriasis/PsA market against numerous approved biologics targeting TNFα, IL-17, IL-23, and JAK pathways. Its differentiation is its novel BAMBI target and unique dual mechanism aiming to rebalance the immune system, rather than block a single cytokine. Success hinges on demonstrating clinical superiority, particularly in refractory patients.